<DOC>
	<DOCNO>NCT00543803</DOCNO>
	<brief_summary>This observational study suppose ass ( condition clinical practice daily routine ) whether treatment Viramune ( nevirapine ) combination Truvada ( tenofovir emtricitabine ) durably suppress viral load limit detection maintain suppression viral replication ( HIV-RNA limit detection ) achieve previous anti-retroviral combination therapy switch combination treatment Viramune ( nevirapine ) Truvada ( tenofovir emtricitabine ) .</brief_summary>
	<brief_title>Observational Non-interventional Study With Viramune® Combination With Truvada® HIV-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Inclusion criterion male female adult HIV type 1 infected patient , either treat previously , whose previous combination treatment PIs fail , switch previous treatment protease inhibitor ( PI ) nonnucleoside reverse transcriptase inhibitor ( NNRT ) I due side effect intolerability achieve suppression viral load limit detection . Viramune ( nevirapine ) indicate part combination therapy antiviral treatment HIV1 infect patient advanced progressive immunodeficiency . Truvada ( tenofovir emtricitabine ) indicate antiretroviral combination therapy treatment HIV1 infect adult . Exclusion criterion Age &lt; 18 year Pregnant female patient Hypersensitivity active substance excipients Viramune ( nevirapine ) Truvada ( tenofovir emtricitabine ) . Viramune ( nevirapine ) readministered patient require permanent discontinuation severe rash , rash accompany constitutional symptom , hypersensitivity reaction , clinical hepatitis due nevirapine . Viramune ( nevirapine ) use patient severe hepatic impairment ( ChildPugh C ) pretreatment aspartine transaminase ( ASAT ) alanine transaminase ( ALAT ) &gt; 5 upper limit normal ( ULN ) baseline ASAT/ALAT stabilise &lt; 5 ULN . Viramune ( nevirapine ) readministered patient previously ASAT ALAT &gt; 5 ULN Viramune ( nevirapine ) therapy recurrence liver function abnormality upon readministration Viramune ( nevirapine ) Herbal preparation contain St Johns wort ( Hypericum perforatum ) must use take Viramune ( nevirapine ) due risk decrease plasma concentration reduce clinical effect nevirapine The available pharmacokinetic data suggest concomitant use rifampicin Viramune ( nevirapine ) recommend .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>